Granulomatous mastitis (GM) is a rare disease, particularly among men. Herein, we present a case of GM diagnosed in a 63-year-old male patient who showed reduction in the tumor size during 3 months of observation.
A 34-year-old woman with breast cancer and the BRCA2: p.Gln3047Ter was
treated with olaparib. After tumor progression, cancer genomic profiling
testing revealed the BRCA2 p.Gln3047Ter and p.Gln3047Tyr, with 48.9%
and 0.37% allele frequency, respectively. These findings shed light on
reversion mutation as a resistance mechanism to olaparib in breast
cancer.
A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer.
Granulomatous mastitis (GM) is a rare disease, particularly amongst men.
Herein, we present a case of GM diagnosed in a 63-year-old male patient
who showed reduction in the tumor size during 3 months of observation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.